Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Primidone”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 865 records · Page 48Linked to original sources

Therapy of myoclonus.

The treatment of myoclonus is mainly based on the pathophysiological origin of the neuronal discharges producing the jerks. Myoclonus of cortical origin responds best to treatment. Drugs commonly used to treat epilepsy are usually capable of controlling action and stimuli-sensitive cortical myoclonus. Piracetam (6-20 g/day), clonazepam (2-12 mg/day), sodium valproate (1,200-3,000 mg/day), and primidone (500-1,000 mg/day) are the most useful ones, often given in combination. Myoclonus of non-cortical origin, i.e. reticular reflex myoclonus or spinal myoclonus, may respond to serotoninergic drugs and clonazepam, but there is much less scientific documentation and rationale behind the therapeutic approach to these different forms, and hence greater variability in the response. No specific drug treatment is yet available for negative myoclonus (Asterixis and postural lapses).

Electromyography↗

Seizures and epilepsy in the elderly.

Seizures and epilepsy in the elderly are an important and increasingly common clinical problem. Major known causes include cerebrovascular disease, brain tumor, degenerative disorders such as Alzheimer disease and cerebral amyloid angiopathy, and toxic-metabolic syndromes such as nonketotic hyperglycemia, postcardiac arrest, and drug-induced seizures. Recognition of seizures may be complicated by relatively unique clinical presentations and differential diagnosis. Nonconvulsive status epilepticus may present as recurrent episodes of confusion. The electroencephalogram is less useful than in the pediatric age group, but has a role in the evaluation of a first seizure and may rarely show characteristic patterns, such as poststroke periodic lateralized epileptiform discharges. Convulsive status, especially that associated with drug toxicity, is associated with increased mortality in the elderly. Pharmacological treatment is complicated by age-related changes in pharmacokinetics and pharmacodynamics and drug-drug and drug-disease interactions. Some of the new antiepileptic drugs may offer advantages for use in the elderly. Oxcarbazepine has fewer drug interactions than carbamazepine, and gabapentin has one, a reduction of felbamate renal elimination. Vigabatrin causes little cognitive dysfunction, while drugs that reduce excitatory amino acid neurotransmission, such as lamotrigine and felbamate, have potentially protective effects in patients with ischemic cerebrovascular disease. The use of barbiturates, primidone, the benzodiazepine clobazam, and the calcium blockers flunarizine and cinnarizine should preferably be avoided in the elderly.

Aged↗

[Which drugs should be chosen for the different types of epilepsy?].

The selection of an antiepileptic drug is based primarily on its efficacy. When the efficacy of several antiepileptic drugs is similar, what is frequently observed, their safety, pharmaco-kinetics, and cost should be also considered. Efficacy, dose-dependent and idiosyncratic toxicity, pharmacokinetics features, and interactions of phenobarbital, phenytoin, carbamazepine, valproate, felbamate, gabapentin, lamotrigine and vigabatrin are comparatively analyzed, and drugs of choice for generalized epilepsies and partial epilepsies are proposed. It is concluded that phenobarbital, primidone and phenytoin are being replaced by carbamazepine and valproate as first choice drugs for most types of epilepsies due to a similar (and even better) efficacy, besides a better safety profile and easier dosing. Features of new antiepileptic drugs make they adequate to be used as add-on drugs in treatment-resistant patients: lamotrigine and felbamate are effective in Lennox-Gastaut syndrome, and vigabatrin in West syndrome, most of the new antiepileptic drugs are well tolerated and show less interactions than the standard ones. However, the efficacy and safety of the new antiepileptic drugs in monotherapy, and their long-term safety have not been yet established, and they will cost more than the standard drugs. Therefore, the new antiepileptic drugs are currently considered as second choice drugs, although vigabatrin has been proposed as a first choice drug in West syndrome.

Anticonvulsants↗